Pages that link to "Q80185991"
Jump to navigation
Jump to search
The following pages link to Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer (Q80185991):
Displaying 32 items.
- Dose-Dense Chemotherapy in Metastatic Breast Cancer: Shortening the Time Interval for a Better Therapeutic Index (Q26751245) (← links)
- The war on cancer: a military perspective (Q28083060) (← links)
- Learning therapeutic lessons from metastasis suppressor proteins (Q30435922) (← links)
- Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics (Q33803564) (← links)
- Fine-tuning anti-tumor immunotherapies via stochastic simulations. (Q34248082) (← links)
- Tumors That Acquire Resistance to Low-Dose Metronomic Cyclophosphamide Retain Sensitivity to Maximum Tolerated Dose Cyclophosphamide (Q34497992) (← links)
- Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer (Q35684466) (← links)
- Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. (Q36221386) (← links)
- Capecitabine combined with (-)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts (Q36224291) (← links)
- Targeted expression of BikDD combined with metronomic doxorubicin induces synergistic antitumor effect through Bax activation in hepatocellular carcinoma (Q36414302) (← links)
- Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer (Q36449367) (← links)
- A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. (Q36615612) (← links)
- Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer (Q36618871) (← links)
- Multidisciplinary frontiers in breast cancer management: a surgeon's perspective (Q36733992) (← links)
- Metronomic chemotherapy: changing the paradigm that more is better (Q37158779) (← links)
- Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. (Q37160109) (← links)
- Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs (Q37336482) (← links)
- Tumoral angiogenesis and breast cancer (Q37416806) (← links)
- Metronomic chemotherapy for metastatic prostate cancer: a 'young' concept for old patients? (Q37784481) (← links)
- Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer (Q37864901) (← links)
- Clinical overview of metronomic chemotherapy in breast cancer. (Q38560651) (← links)
- Knockdown of Hypoxia-Inducible Factor 1α Improved the Efficacy of Low-Dose Metronomic Chemotherapy of Paclitaxel in Human Colon Cancer Xenografts (Q38749231) (← links)
- Dalteparin, a low‐molecular‐weight heparin, promotes angiogenesis mediated by heparin‐binding VEGF‐A in vivo (Q41212817) (← links)
- Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis (Q42554491) (← links)
- Metronomic dosing enhances the anti-angiogenic effect of epothilone B. (Q42563683) (← links)
- Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer (Q47149222) (← links)
- Clinical trials in older, less fit populations: an unmet need? (Q50056554) (← links)
- Explorative Analysis of Low-Dose Metronomic Chemotherapy with Cyclophosphamide and Methotrexate in a Cohort of Metastatic Breast Cancer Patients (Q57495758) (← links)
- Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide (Q58785196) (← links)
- Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience (Q64071354) (← links)
- Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer (Q64089308) (← links)
- Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas (Q83940496) (← links)